Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.

Cancer medicine - 1 Jun 2024

Wang Li, Wu Yueran, Ren Zhixuan, Chu Xiangling, Chen Jianing, Liu Li, Zhao Jing, Yu Xin, Xie Mengqing, Su Chunxia

Abstract excerpt

OBJECTIVES: HER2 is an infrequently mutated driver gene in non-small cell lung cancer (NSCLC). At present, there has been no comprehensive large-scale clinical study to establish the optimal first-line treatment strategy for advanced lung adenocarcinoma (LUAD) with HER2-Mutant. Besides that, the effectiveness and safety of pyrotinib, a pan-HER inhibitor, in the context of NSCLC are still undergoing investigation....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aminoquinolines

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immune Checkpoint Inhibitors

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 38923311
DOI: 10.1002/cam4.7335
PMCID: PMC11194746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.PMID 38923311Read ↗

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSemantic proximity Read ↗

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.Semantic proximity Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Semantic proximity Read ↗

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation.Semantic proximity Read ↗

Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Semantic proximity Read ↗

<p>Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report</p>Semantic proximity Read ↗

Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)Semantic proximity Read ↗

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].Semantic proximity Read ↗

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.Semantic proximity Read ↗

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read ↗

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.